ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1067

Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease

Takahisa Gono1, Yuka Okazaki1 and Masataka Kuwana2, 1Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan

Meeting: ACR Convergence 2020

Keywords: dermatomyositis, interferon, interstitial lung disease, Monocytes/macrophages

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Muscle Biology, Myositis & Myopathies Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is associated with interstitial lung disease (ILD), which often represents rapidly progressive course and fatal outcomes. Circulating levels of ferritin were remarkably increased in patients with anti-MDA5-associated ILD, especially in those with rapidly progressive ILD, suggesting involvement of monocyte/macrophage activation in the pathogenic process. However, stimuli that trigger activation of monocytes/macrophages in anti-MDA5-associated ILD still remain unknown. In this study, we investigated molecules and pathways involved in activated monocytes in circulation from patients with anti-MDA5-associated ILD, using microarray expression profiling combined with the integrated miRNA-mRNA association analysis.

Methods: We first examined comprehensive expression profiling of mRNA and miRNA by a microarray system using circulating CD14+ monocytes from 3 untreated patients with anti-MDA5-associated ILD and 3 healthy controls (HCs). Then, integrated miRNA-mRNA association analysis was conducted to identify molecules related to disease pathways and their regulator effect networks using Ingenuity Pathway Analysis (IPA) system. The relevant gene expression levels were validated by real-time PCR using additional circulating monocyte samples obtained from 5 untreated patients with anti-MDA5-associated ILD, 5 patients with anti-aminoacyl tRNA synthetase (ARS)-associated ILD, and 5 HCs.

Results: Twenty-six significant matched pairs of differentially down-regulated miRNA and up-regulated mRNA were identified by IPA, and 6 relevant genes associated with disease pathways included IFIT2, IFIT3, MX1, IRF7, CCL2 and CLU. The major relevant genes of our dataset were type 1 interferon (IFN)-inducible genes. The regulator effect network analysis identified 5 predicted upstream regulators, including IFN-β, toll-like receptor (TLR) 3, TLR7, TLR9, and SPI1. Anti-viral infection pathway was identified as the predicted downstream effect involved with those 6 relevant genes. The mRNA expressions levels of 6 genes associated with disease pathways were confirmed to be higher in patients with anti-MDA5-associated ILD than in those with anti-ARS-associated ILD or HCs, and were declined after immunosuppressive treatment in patients with anti-MDA5-associated ILD.

Conclusion: Anti-viral proinflammatory pathways are activated in circulating monocytes from patients with anti-MDA5-associated ILD, suggesting roles of viral infection in triggering this devastating condition.


Disclosure: T. Gono, Bristol Myers Squibb, 1, Chugai pharmaceutical, 1, Ono pharmaceutical, 1, Boehringer Ingelheim, 1, Janssen, 1; Y. Okazaki, None; M. Kuwana, Ono Pharmaceutical, 2, 8, Chugai, 2, 8, Astellas, 8, Mitsubishi Tanabe Pharma Corporation, 2, 8, AbbVie Inc., 8, Eisai Co., Ltd., 8.

To cite this abstract in AMA style:

Gono T, Okazaki Y, Kuwana M. Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anti-viral-proinflammatory-phenotype-in-circulating-monocytes-from-patients-with-anti-melanoma-differentiation-associated-gene-5-antibody-associated-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-viral-proinflammatory-phenotype-in-circulating-monocytes-from-patients-with-anti-melanoma-differentiation-associated-gene-5-antibody-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology